R. Moroose

发表

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

Sung-Bae Kim, J. Baselga, Bing-he Xu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.

J. Berlin, A. Bardia, J. Lang, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.

A. Bardia, D. Juric, Q. Hong, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).

F. Kabbinavar, D. Slamon, J. Glaspy, 2010, Clinical breast cancer.

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery.

J. Francis, G. Palmer, R. Moroose, 2003, The Annals of thoracic surgery.

Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood

A. Khaled, A. Khaled, S. Litherland, 2022, PloS one.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful Use of Bivalirudin in the Treatment of Patients Suspected, or at Risk of, Heparin-Induced Thrombocytopenia.

J. Francis, R. Moroose, Alane J. Drexler, 2004 .

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy

P. Kelly, J. Rineer, Zhenjun Ma, 2017, International journal of breast cancer.

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors

J. Chakrabarti, Z. Wainberg, J. Hoffman, 2019, Anti-cancer drugs.

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment

J. Chakrabarti, Z. Wainberg, S. Piha-Paul, 2022, British Journal of Clinical Pharmacology.

Gamma-glutamylcysteine synthetase deficiency and hemolytic anemia.

L. Forman, E. Beutler, T. Gelbart, 1990, Blood.

Lifestyle and Breast Cancer Incidence and Survival

R. Moroose, Ana Elisa Cuesta Fernandez, 2015 .

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

J. Mackey, W. Eiermann, T. Pintér, 2011, The Lancet. Oncology.

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

A. Bardia, H. Rugo, J. Diamond, 2019, The New England journal of medicine.

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

D. Elashoff, R. Hermann, C. Vogel, 2009 .

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

A. Bardia, D. Juric, J. Diamond, 2018 .

Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

J. Berlin, A. Bardia, T. Traina, 2016 .

Surreptitious Ingestion of a Long-Acting Vitamin K Antagonist/Rodenticide, Brodifacoum: Clinical and Metabolic Studies of Three Cases

B. Furie, J. Weitzel, M. Murphy, 1990 .

Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases.

B. Furie, J. Weitzel, M. Murphy, 1990, Blood.

In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer

B. Loftus, R. Watson, D. Hollywood, 2007, British Journal of Cancer.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

S. Loi, G. Hortobagyi, A. Bardia, 2023, Therapeutic advances in medical oncology.

AND PLATELET FUNCTION

L. Hoyer, R. Moroose, 1986 .

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).

D. Slamon, J. O’Shaughnessy, P. Ordentlich, 2020 .

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

S. Loi, G. Hortobagyi, A. Bardia, 2023, Journal of Clinical Oncology.

von Willebrand factor and platelet function.

L. Hoyer, R. Moroose, 1986, Annual review of medicine.

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

J. Berlin, A. Bardia, J. Diamond, 2015 .

Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study.

Miguel Martín, J. Cortés, C. Saura, 2009 .

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

G. Hortobagyi, D. Yardley, M. Ruíz-Borrego, 2024, The New England journal of medicine.